AstraZeneca at a glance

A global biopharmaceutical business delivering medicines to patients through innovative science and excellence in development and commercialisation.

Our Purpose is to push the boundaries of science to deliver life-changing medicines. We want to be valued and trusted by our stakeholders as a source of great medicines over the long term.

Our strategic priorities
Reflect how we are working to achieve our Purpose

1. Achieve Scientific Leadership
2. Return to Growth
3. Be a Great Place to Work

A science-led innovation strategy
Strategy and Key Performance Indicators from page 17.

Distinctive R&D capabilities:
Small molecules, oligonucleotides and other emerging drug platforms, as well as biologic medicines, including immunotherapies, and innovative delivery devices

11 new molecular entities (NMEs) in Phase III/pivotal Phase II or under regulatory review covering 19 indications

Broad R&D platform in three main areas
Achieve Scientific Leadership from page 23 and Therapy Area Review from page 46.

Oncology
Our ambition is to eliminate cancer as a cause of death through scientific discovery and collaborations. We seek to achieve this by means of exploiting the power of four scientific platforms

Cardiovascular & Metabolic Diseases
We are following the science to transform how cardiovascular, renal and metabolic diseases are understood, interact and impact one another

Respiratory
We aim to transform the treatment of respiratory disease with our growing portfolio of medicines and scientific research targeting disease modification

We are also selectively active in the areas of autoimmunity, neuroscience and infection

Portfolio of specialty and primary care products (Product Sales)

<table>
<thead>
<tr>
<th>Disease Area</th>
<th>2017 Sales (in millions)</th>
<th>2016 Sales (in millions)</th>
<th>2015 Sales (in millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology</td>
<td>$4,024m</td>
<td>$4,383m</td>
<td>$2,835m</td>
</tr>
<tr>
<td>Cardiovascular &amp; Metabolic Diseases</td>
<td>$7,266m</td>
<td>$8,116m</td>
<td>$9,489m</td>
</tr>
<tr>
<td>Respiratory</td>
<td>$4,706m</td>
<td>$4,753m</td>
<td>$4,987m</td>
</tr>
<tr>
<td>Other Disease Areas</td>
<td>$4,156m</td>
<td>$5,067m</td>
<td>$6,340m</td>
</tr>
</tbody>
</table>

Tafinlar sales up 126% (126% at CER) and approved in more than 60 markets

Brilinta sales of $1,079 million, up 29% (29% at CER) and Forxiga sales of $1,074 million, up 29% (28% at CER)

Sales of Onplaz were down by 15% (16% at CER) to $611 million

Legacy sales: Crestor down 30% (30% at CER) to $2,365 million

FluMist/Fluenz sales of $78 million, down 25% (28% at CER)
Global commercial presence, with strength in Emerging Markets (Product Sales)

<table>
<thead>
<tr>
<th>Region</th>
<th>2016 Sales</th>
<th>% of Total</th>
<th>2015 Sales</th>
<th>% of Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>$6,169m</td>
<td>31%</td>
<td>$9,474m</td>
<td>31%</td>
</tr>
<tr>
<td>Emerging Markets</td>
<td>$6,149m</td>
<td>30%</td>
<td>$5,822m</td>
<td>29%</td>
</tr>
<tr>
<td>Europe</td>
<td>$4,753m</td>
<td>24%</td>
<td>$5,064m</td>
<td>22%</td>
</tr>
<tr>
<td>Established</td>
<td>$3,081m</td>
<td>15%</td>
<td>$3,022m</td>
<td>13%</td>
</tr>
</tbody>
</table>

Commercial Highlights:
- Growth Platforms grew by 5% (6% at CER) in 2017 and represented 68% of Total Revenue
- Emerging Markets: Sales growth of 6% (8% at CER), in line with long-term ambitions. China sales in the year grew by 12% (15% at CER), supported by the launches of new medicines.
- New CVMD: Sales growth of 9% (9% at CER). Strong performances from Farxiga and Brilinta, with sales exceeding $1 billion in 2017. Respiratory: Sales declined by 1% (1% at CER). Sales of Symbicort declined by 6% (6% at CER) and Pulmicort sales rose by 11% (12% at CER).
- Japan: 1% growth in sales (4% at CER), underpinned by the growth of Tagrisso and Forxiga, partly mitigated by the impact of the entry of generic competition to Crestor in the second half of the year.
- New Oncology: Sales growth of 98% (98% at CER). Sales of Tagrisso reached $955 million to become AstraZeneca’s largest-selling Oncology medicine.

Our talented employees:
- Committed to achieving our Purpose in a sustainable way and upholding our Values by fostering a strong AstraZeneca culture
- 61,100 employees
  - 2016: 59,700
  - 2015: 61,500
- 100% of employees trained in new Code of Ethics

Our capital-allocation priorities:
- Striking a balance between the interests of the business, our financial creditors and shareholders, and supporting our progressive dividend policy

Distributions to shareholders
- Dividends
  - $3,519m
    - 2016: $3,561m
    - 2015: $3,486m
  - Proceeds from issue of shares
    - $(43)m
      - 2016: $(47)m
      - 2015: $(43)m
- Total
  - $3,476m
    - 2016: $3,514m
    - 2015: $3,443m

Dividends per Ordinary Share for 2017
- 1st interim dividend
  - $0.90
    - Pence: 68.9
    - SEK: 7.40
    - Payment date: 11 September 2017
- 2nd interim dividend
  - $1.90
    - Pence: 133.6
    - SEK: 14.97
    - Payment date: 19 March 2018
- Total
  - $2.80
    - Pence: 202.5
    - SEK: 22.37
    - 2016: $2.80
    - 2015: $2.80